David DiBardino, MD

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how it's delivered to tumors.